nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—ALB—lung cancer	0.148	0.512	CbGaD
Norethindrone—ABCB1—lung cancer	0.141	0.488	CbGaD
Norethindrone—ALB—Gefitinib—lung cancer	0.0298	0.0571	CbGbCtD
Norethindrone—CYP3A5—Gefitinib—lung cancer	0.0239	0.0459	CbGbCtD
Norethindrone—CYP3A5—Teniposide—lung cancer	0.0232	0.0445	CbGbCtD
Norethindrone—CYP2C19—Gefitinib—lung cancer	0.0193	0.037	CbGbCtD
Norethindrone—CYP2C19—Teniposide—lung cancer	0.0187	0.0359	CbGbCtD
Norethindrone—ALB—Erlotinib—lung cancer	0.0176	0.0338	CbGbCtD
Norethindrone—CYP3A7—Paclitaxel—lung cancer	0.0173	0.0331	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Paclitaxel—lung cancer	0.0173	0.0331	CbGbCtD
Norethindrone—CYP3A7—Irinotecan—lung cancer	0.017	0.0327	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Irinotecan—lung cancer	0.017	0.0327	CbGbCtD
Norethindrone—ABCB1—Topotecan—lung cancer	0.017	0.0326	CbGbCtD
Norethindrone—ALB—Irinotecan—lung cancer	0.0159	0.0305	CbGbCtD
Norethindrone—ABCB1—Gefitinib—lung cancer	0.0156	0.0299	CbGbCtD
Norethindrone—CYP3A5—Crizotinib—lung cancer	0.0147	0.0281	CbGbCtD
Norethindrone—CYP3A5—Erlotinib—lung cancer	0.0141	0.0271	CbGbCtD
Norethindrone—CYP3A5—Paclitaxel—lung cancer	0.013	0.0248	CbGbCtD
Norethindrone—CYP3A5—Irinotecan—lung cancer	0.0128	0.0245	CbGbCtD
Norethindrone—CYP3A7-CYP3A51P—Docetaxel—lung cancer	0.0125	0.0239	CbGbCtD
Norethindrone—CYP3A7—Docetaxel—lung cancer	0.0125	0.0239	CbGbCtD
Norethindrone—ABCB1—Vinorelbine—lung cancer	0.012	0.023	CbGbCtD
Norethindrone—CYP3A5—Etoposide—lung cancer	0.0102	0.0196	CbGbCtD
Norethindrone—CYP3A4—Topotecan—lung cancer	0.0102	0.0196	CbGbCtD
Norethindrone—ABCB1—Crizotinib—lung cancer	0.00955	0.0183	CbGbCtD
Norethindrone—CYP3A5—Docetaxel—lung cancer	0.00936	0.018	CbGbCtD
Norethindrone—CYP3A4—Gefitinib—lung cancer	0.00933	0.0179	CbGbCtD
Norethindrone—ABCB1—Gemcitabine—lung cancer	0.00933	0.0179	CbGbCtD
Norethindrone—ABCB1—Erlotinib—lung cancer	0.00921	0.0177	CbGbCtD
Norethindrone—CYP3A4—Teniposide—lung cancer	0.00905	0.0173	CbGbCtD
Norethindrone—ABCB1—Paclitaxel—lung cancer	0.00843	0.0162	CbGbCtD
Norethindrone—ALB—Methotrexate—lung cancer	0.00841	0.0161	CbGbCtD
Norethindrone—ABCB1—Irinotecan—lung cancer	0.00832	0.0159	CbGbCtD
Norethindrone—ABCB1—Vinblastine—lung cancer	0.00739	0.0142	CbGbCtD
Norethindrone—CYP3A4—Vinorelbine—lung cancer	0.00719	0.0138	CbGbCtD
Norethindrone—ABCB1—Cisplatin—lung cancer	0.00678	0.013	CbGbCtD
Norethindrone—ABCB1—Etoposide—lung cancer	0.00666	0.0128	CbGbCtD
Norethindrone—ABCB1—Docetaxel—lung cancer	0.00609	0.0117	CbGbCtD
Norethindrone—CYP3A4—Crizotinib—lung cancer	0.00572	0.011	CbGbCtD
Norethindrone—CYP3A4—Erlotinib—lung cancer	0.00552	0.0106	CbGbCtD
Norethindrone—CYP3A4—Paclitaxel—lung cancer	0.00505	0.00968	CbGbCtD
Norethindrone—CYP3A4—Irinotecan—lung cancer	0.00498	0.00955	CbGbCtD
Norethindrone—ABCB1—Doxorubicin—lung cancer	0.00454	0.00871	CbGbCtD
Norethindrone—CYP3A4—Vinblastine—lung cancer	0.00443	0.00849	CbGbCtD
Norethindrone—ABCB1—Methotrexate—lung cancer	0.0044	0.00844	CbGbCtD
Norethindrone—CYP3A4—Etoposide—lung cancer	0.00399	0.00765	CbGbCtD
Norethindrone—CYP3A4—Docetaxel—lung cancer	0.00365	0.007	CbGbCtD
Norethindrone—CYP3A4—Doxorubicin—lung cancer	0.00272	0.00522	CbGbCtD
Norethindrone—Hydrocortisone—ANXA1—lung cancer	0.000536	0.254	CrCbGaD
Norethindrone—Testosterone Propionate—UGT1A1—lung cancer	0.000464	0.22	CrCbGaD
Norethindrone—Flatulence—Cisplatin—lung cancer	0.000159	0.00123	CcSEcCtD
Norethindrone—Erythema multiforme—Paclitaxel—lung cancer	0.000157	0.00122	CcSEcCtD
Norethindrone—Hypersensitivity—Vinblastine—lung cancer	0.000156	0.00121	CcSEcCtD
Norethindrone—Acute coronary syndrome—Docetaxel—lung cancer	0.000155	0.0012	CcSEcCtD
Norethindrone—Renal failure—Docetaxel—lung cancer	0.000154	0.0012	CcSEcCtD
Norethindrone—Myocardial infarction—Docetaxel—lung cancer	0.000154	0.00119	CcSEcCtD
Norethindrone—Immune system disorder—Etoposide—lung cancer	0.000153	0.00119	CcSEcCtD
Norethindrone—Drospirenone—PTGS2—lung cancer	0.000152	0.0721	CrCbGaD
Norethindrone—Anaphylactoid reaction—Methotrexate—lung cancer	0.000152	0.00118	CcSEcCtD
Norethindrone—Asthenia—Vinblastine—lung cancer	0.000152	0.00118	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000152	0.00118	CcSEcCtD
Norethindrone—Fatigue—Vinorelbine—lung cancer	0.000151	0.00118	CcSEcCtD
Norethindrone—Hypersensitivity—Topotecan—lung cancer	0.000151	0.00117	CcSEcCtD
Norethindrone—Immune system disorder—Paclitaxel—lung cancer	0.00015	0.00117	CcSEcCtD
Norethindrone—Alopecia—Etoposide—lung cancer	0.00015	0.00116	CcSEcCtD
Norethindrone—Hepatobiliary disease—Docetaxel—lung cancer	0.000148	0.00115	CcSEcCtD
Norethindrone—Asthenia—Topotecan—lung cancer	0.000147	0.00114	CcSEcCtD
Norethindrone—Hydrocortisone—ABCG2—lung cancer	0.000147	0.0697	CrCbGaD
Norethindrone—Alopecia—Paclitaxel—lung cancer	0.000147	0.00114	CcSEcCtD
Norethindrone—Thrombophlebitis—Doxorubicin—lung cancer	0.000147	0.00114	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000146	0.00113	CcSEcCtD
Norethindrone—Asthenia—Erlotinib—lung cancer	0.000146	0.00113	CcSEcCtD
Norethindrone—Mental disorder—Paclitaxel—lung cancer	0.000146	0.00113	CcSEcCtD
Norethindrone—Pruritus—Topotecan—lung cancer	0.000145	0.00113	CcSEcCtD
Norethindrone—Oedema—Irinotecan—lung cancer	0.000145	0.00112	CcSEcCtD
Norethindrone—Anaphylactic shock—Irinotecan—lung cancer	0.000145	0.00112	CcSEcCtD
Norethindrone—Photosensitivity—Doxorubicin—lung cancer	0.000145	0.00112	CcSEcCtD
Norethindrone—Pruritus—Erlotinib—lung cancer	0.000144	0.00112	CcSEcCtD
Norethindrone—Gastrointestinal pain—Vinorelbine—lung cancer	0.000144	0.00111	CcSEcCtD
Norethindrone—Flatulence—Paclitaxel—lung cancer	0.000143	0.00111	CcSEcCtD
Norethindrone—Tension—Paclitaxel—lung cancer	0.000142	0.0011	CcSEcCtD
Norethindrone—Haemoglobin—Docetaxel—lung cancer	0.000142	0.0011	CcSEcCtD
Norethindrone—Anaphylactic shock—Gemcitabine—lung cancer	0.000141	0.0011	CcSEcCtD
Norethindrone—Oedema—Gemcitabine—lung cancer	0.000141	0.0011	CcSEcCtD
Norethindrone—Hepatitis—Docetaxel—lung cancer	0.000141	0.00109	CcSEcCtD
Norethindrone—Haemorrhage—Docetaxel—lung cancer	0.000141	0.00109	CcSEcCtD
Norethindrone—Nervousness—Paclitaxel—lung cancer	0.00014	0.00109	CcSEcCtD
Norethindrone—Dizziness—Vinblastine—lung cancer	0.00014	0.00108	CcSEcCtD
Norethindrone—Convulsion—Cisplatin—lung cancer	0.00014	0.00108	CcSEcCtD
Norethindrone—Urticaria—Vinorelbine—lung cancer	0.000139	0.00108	CcSEcCtD
Norethindrone—Mood swings—Methotrexate—lung cancer	0.000139	0.00108	CcSEcCtD
Norethindrone—Abdominal pain—Vinorelbine—lung cancer	0.000139	0.00108	CcSEcCtD
Norethindrone—Connective tissue disorder—Docetaxel—lung cancer	0.000138	0.00108	CcSEcCtD
Norethindrone—Skin disorder—Gemcitabine—lung cancer	0.000137	0.00106	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000136	0.00106	CcSEcCtD
Norethindrone—Dizziness—Topotecan—lung cancer	0.000136	0.00105	CcSEcCtD
Norethindrone—Vomiting—Vinblastine—lung cancer	0.000134	0.00104	CcSEcCtD
Norethindrone—Dizziness—Erlotinib—lung cancer	0.000134	0.00104	CcSEcCtD
Norethindrone—Progesterone—CYP2A6—lung cancer	0.000134	0.0635	CrCbGaD
Norethindrone—Renal impairment—Doxorubicin—lung cancer	0.000134	0.00104	CcSEcCtD
Norethindrone—Erythema multiforme—Docetaxel—lung cancer	0.000133	0.00103	CcSEcCtD
Norethindrone—Breast disorder—Methotrexate—lung cancer	0.000133	0.00103	CcSEcCtD
Norethindrone—Headache—Vinblastine—lung cancer	0.000132	0.00103	CcSEcCtD
Norethindrone—Purpura—Doxorubicin—lung cancer	0.000132	0.00102	CcSEcCtD
Norethindrone—Anaphylactic shock—Cisplatin—lung cancer	0.000131	0.00102	CcSEcCtD
Norethindrone—Oedema—Cisplatin—lung cancer	0.000131	0.00102	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Doxorubicin—lung cancer	0.000131	0.00102	CcSEcCtD
Norethindrone—Insomnia—Irinotecan—lung cancer	0.000131	0.00102	CcSEcCtD
Norethindrone—Vomiting—Topotecan—lung cancer	0.00013	0.00101	CcSEcCtD
Norethindrone—Rash—Topotecan—lung cancer	0.000129	0.001	CcSEcCtD
Norethindrone—Hypersensitivity—Vinorelbine—lung cancer	0.000129	0.001	CcSEcCtD
Norethindrone—Dermatitis—Topotecan—lung cancer	0.000129	0.001	CcSEcCtD
Norethindrone—Vomiting—Erlotinib—lung cancer	0.000129	0.001	CcSEcCtD
Norethindrone—Somnolence—Irinotecan—lung cancer	0.000129	0.001	CcSEcCtD
Norethindrone—Headache—Topotecan—lung cancer	0.000129	0.000998	CcSEcCtD
Norethindrone—Rash—Erlotinib—lung cancer	0.000128	0.000994	CcSEcCtD
Norethindrone—Dermatitis—Erlotinib—lung cancer	0.000128	0.000993	CcSEcCtD
Norethindrone—Convulsion—Etoposide—lung cancer	0.000128	0.000993	CcSEcCtD
Norethindrone—Skin disorder—Cisplatin—lung cancer	0.000128	0.000992	CcSEcCtD
Norethindrone—Insomnia—Gemcitabine—lung cancer	0.000128	0.000991	CcSEcCtD
Norethindrone—Dyspepsia—Irinotecan—lung cancer	0.000127	0.00099	CcSEcCtD
Norethindrone—Immune system disorder—Docetaxel—lung cancer	0.000127	0.000988	CcSEcCtD
Norethindrone—Headache—Erlotinib—lung cancer	0.000127	0.000988	CcSEcCtD
Norethindrone—Pain in extremity—Doxorubicin—lung cancer	0.000127	0.000987	CcSEcCtD
Norethindrone—Asthenia—Vinorelbine—lung cancer	0.000126	0.000978	CcSEcCtD
Norethindrone—Nausea—Vinblastine—lung cancer	0.000125	0.000974	CcSEcCtD
Norethindrone—Somnolence—Gemcitabine—lung cancer	0.000125	0.000974	CcSEcCtD
Norethindrone—Convulsion—Paclitaxel—lung cancer	0.000125	0.000973	CcSEcCtD
Norethindrone—Migraine—Doxorubicin—lung cancer	0.000125	0.000971	CcSEcCtD
Norethindrone—Affect lability—Doxorubicin—lung cancer	0.000125	0.000971	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Irinotecan—lung cancer	0.000125	0.000971	CcSEcCtD
Norethindrone—Fatigue—Irinotecan—lung cancer	0.000125	0.000969	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000125	0.000969	CcSEcCtD
Norethindrone—Alopecia—Docetaxel—lung cancer	0.000124	0.000967	CcSEcCtD
Norethindrone—Pruritus—Vinorelbine—lung cancer	0.000124	0.000964	CcSEcCtD
Norethindrone—Mental disorder—Docetaxel—lung cancer	0.000123	0.000958	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000122	0.00095	CcSEcCtD
Norethindrone—Nausea—Topotecan—lung cancer	0.000122	0.000947	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000122	0.000946	CcSEcCtD
Norethindrone—Fatigue—Gemcitabine—lung cancer	0.000122	0.000944	CcSEcCtD
Norethindrone—Nausea—Erlotinib—lung cancer	0.000121	0.000937	CcSEcCtD
Norethindrone—Anaphylactic shock—Etoposide—lung cancer	0.00012	0.000935	CcSEcCtD
Norethindrone—Mood swings—Doxorubicin—lung cancer	0.00012	0.000935	CcSEcCtD
Norethindrone—Gastrointestinal pain—Irinotecan—lung cancer	0.000118	0.000919	CcSEcCtD
Norethindrone—Anaphylactic shock—Paclitaxel—lung cancer	0.000118	0.000917	CcSEcCtD
Norethindrone—Oedema—Paclitaxel—lung cancer	0.000118	0.000917	CcSEcCtD
Norethindrone—Skin disorder—Etoposide—lung cancer	0.000117	0.000908	CcSEcCtD
Norethindrone—Dizziness—Vinorelbine—lung cancer	0.000116	0.000901	CcSEcCtD
Norethindrone—Photosensitivity reaction—Methotrexate—lung cancer	0.000116	0.000899	CcSEcCtD
Norethindrone—Breast disorder—Doxorubicin—lung cancer	0.000115	0.000892	CcSEcCtD
Norethindrone—Skin disorder—Paclitaxel—lung cancer	0.000115	0.000891	CcSEcCtD
Norethindrone—Abdominal pain—Irinotecan—lung cancer	0.000114	0.000889	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Cisplatin—lung cancer	0.000113	0.000881	CcSEcCtD
Norethindrone—Testosterone—ABCG2—lung cancer	0.000113	0.0537	CrCbGaD
Norethindrone—Drowsiness—Methotrexate—lung cancer	0.000113	0.000878	CcSEcCtD
Norethindrone—Depression—Methotrexate—lung cancer	0.000113	0.000876	CcSEcCtD
Norethindrone—Vomiting—Vinorelbine—lung cancer	0.000112	0.000867	CcSEcCtD
Norethindrone—Renal failure—Methotrexate—lung cancer	0.000111	0.000863	CcSEcCtD
Norethindrone—Rash—Vinorelbine—lung cancer	0.000111	0.00086	CcSEcCtD
Norethindrone—Dermatitis—Vinorelbine—lung cancer	0.000111	0.000859	CcSEcCtD
Norethindrone—Abdominal distension—Doxorubicin—lung cancer	0.000111	0.000859	CcSEcCtD
Norethindrone—Headache—Vinorelbine—lung cancer	0.00011	0.000854	CcSEcCtD
Norethindrone—Somnolence—Etoposide—lung cancer	0.000107	0.000831	CcSEcCtD
Norethindrone—Hepatobiliary disease—Methotrexate—lung cancer	0.000107	0.000831	CcSEcCtD
Norethindrone—Insomnia—Paclitaxel—lung cancer	0.000107	0.000829	CcSEcCtD
Norethindrone—Hypersensitivity—Irinotecan—lung cancer	0.000107	0.000828	CcSEcCtD
Norethindrone—Convulsion—Docetaxel—lung cancer	0.000106	0.000825	CcSEcCtD
Norethindrone—Somnolence—Paclitaxel—lung cancer	0.000105	0.000815	CcSEcCtD
Norethindrone—Nausea—Vinorelbine—lung cancer	0.000104	0.00081	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Etoposide—lung cancer	0.000104	0.000807	CcSEcCtD
Norethindrone—Dyspepsia—Paclitaxel—lung cancer	0.000104	0.000807	CcSEcCtD
Norethindrone—Asthenia—Irinotecan—lung cancer	0.000104	0.000807	CcSEcCtD
Norethindrone—Fatigue—Etoposide—lung cancer	0.000104	0.000806	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000104	0.000805	CcSEcCtD
Norethindrone—Haemoglobin—Methotrexate—lung cancer	0.000102	0.000792	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000102	0.000792	CcSEcCtD
Norethindrone—Fatigue—Paclitaxel—lung cancer	0.000102	0.000791	CcSEcCtD
Norethindrone—Hepatitis—Methotrexate—lung cancer	0.000102	0.000788	CcSEcCtD
Norethindrone—Haemorrhage—Methotrexate—lung cancer	0.000102	0.000788	CcSEcCtD
Norethindrone—Asthenia—Gemcitabine—lung cancer	0.000101	0.000786	CcSEcCtD
Norethindrone—Photosensitivity reaction—Doxorubicin—lung cancer	0.0001	0.000779	CcSEcCtD
Norethindrone—Anaphylactic shock—Docetaxel—lung cancer	0.0001	0.000777	CcSEcCtD
Norethindrone—Oedema—Docetaxel—lung cancer	0.0001	0.000777	CcSEcCtD
Norethindrone—Weight increased—Doxorubicin—lung cancer	9.99e-05	0.000776	CcSEcCtD
Norethindrone—Pruritus—Gemcitabine—lung cancer	9.98e-05	0.000775	CcSEcCtD
Norethindrone—Gastrointestinal pain—Etoposide—lung cancer	9.85e-05	0.000765	CcSEcCtD
Norethindrone—Drowsiness—Doxorubicin—lung cancer	9.79e-05	0.000761	CcSEcCtD
Norethindrone—Skin disorder—Docetaxel—lung cancer	9.72e-05	0.000755	CcSEcCtD
Norethindrone—Hypersensitivity—Cisplatin—lung cancer	9.68e-05	0.000752	CcSEcCtD
Norethindrone—Gastrointestinal pain—Paclitaxel—lung cancer	9.65e-05	0.00075	CcSEcCtD
Norethindrone—Renal failure—Doxorubicin—lung cancer	9.62e-05	0.000748	CcSEcCtD
Norethindrone—Erythema multiforme—Methotrexate—lung cancer	9.6e-05	0.000745	CcSEcCtD
Norethindrone—Dizziness—Irinotecan—lung cancer	9.57e-05	0.000743	CcSEcCtD
Norethindrone—Urticaria—Etoposide—lung cancer	9.56e-05	0.000743	CcSEcCtD
Norethindrone—Abdominal pain—Etoposide—lung cancer	9.52e-05	0.000739	CcSEcCtD
Norethindrone—Asthenia—Cisplatin—lung cancer	9.43e-05	0.000732	CcSEcCtD
Norethindrone—Progesterone—CYP1A1—lung cancer	9.38e-05	0.0444	CrCbGaD
Norethindrone—Urticaria—Paclitaxel—lung cancer	9.38e-05	0.000728	CcSEcCtD
Norethindrone—Abdominal pain—Paclitaxel—lung cancer	9.33e-05	0.000725	CcSEcCtD
Norethindrone—Hepatobiliary disease—Doxorubicin—lung cancer	9.26e-05	0.000719	CcSEcCtD
Norethindrone—Vomiting—Irinotecan—lung cancer	9.2e-05	0.000715	CcSEcCtD
Norethindrone—Immune system disorder—Methotrexate—lung cancer	9.17e-05	0.000712	CcSEcCtD
Norethindrone—Rash—Irinotecan—lung cancer	9.13e-05	0.000709	CcSEcCtD
Norethindrone—Dermatitis—Irinotecan—lung cancer	9.12e-05	0.000708	CcSEcCtD
Norethindrone—Headache—Irinotecan—lung cancer	9.07e-05	0.000704	CcSEcCtD
Norethindrone—Insomnia—Docetaxel—lung cancer	9.05e-05	0.000703	CcSEcCtD
Norethindrone—Alopecia—Methotrexate—lung cancer	8.97e-05	0.000697	CcSEcCtD
Norethindrone—Vomiting—Gemcitabine—lung cancer	8.96e-05	0.000696	CcSEcCtD
Norethindrone—Ethinyl Estradiol—ABCB1—lung cancer	8.9e-05	0.0422	CrCbGaD
Norethindrone—Somnolence—Docetaxel—lung cancer	8.9e-05	0.000691	CcSEcCtD
Norethindrone—Mental disorder—Methotrexate—lung cancer	8.89e-05	0.000691	CcSEcCtD
Norethindrone—Rash—Gemcitabine—lung cancer	8.89e-05	0.000691	CcSEcCtD
Norethindrone—Dermatitis—Gemcitabine—lung cancer	8.88e-05	0.00069	CcSEcCtD
Norethindrone—Hypersensitivity—Etoposide—lung cancer	8.87e-05	0.000689	CcSEcCtD
Norethindrone—Testosterone—CYP1A1—lung cancer	8.87e-05	0.042	CrCbGaD
Norethindrone—Haemoglobin—Doxorubicin—lung cancer	8.83e-05	0.000686	CcSEcCtD
Norethindrone—Headache—Gemcitabine—lung cancer	8.83e-05	0.000686	CcSEcCtD
Norethindrone—Dyspepsia—Docetaxel—lung cancer	8.81e-05	0.000684	CcSEcCtD
Norethindrone—Haemorrhage—Doxorubicin—lung cancer	8.79e-05	0.000683	CcSEcCtD
Norethindrone—Hepatitis—Doxorubicin—lung cancer	8.79e-05	0.000683	CcSEcCtD
Norethindrone—Hypersensitivity—Paclitaxel—lung cancer	8.7e-05	0.000676	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Docetaxel—lung cancer	8.64e-05	0.000671	CcSEcCtD
Norethindrone—Asthenia—Etoposide—lung cancer	8.64e-05	0.000671	CcSEcCtD
Norethindrone—Connective tissue disorder—Doxorubicin—lung cancer	8.64e-05	0.000671	CcSEcCtD
Norethindrone—Fatigue—Docetaxel—lung cancer	8.63e-05	0.00067	CcSEcCtD
Norethindrone—Nausea—Irinotecan—lung cancer	8.6e-05	0.000668	CcSEcCtD
Norethindrone—Pruritus—Etoposide—lung cancer	8.52e-05	0.000662	CcSEcCtD
Norethindrone—Methyltestosterone—ALB—lung cancer	8.51e-05	0.0403	CrCbGaD
Norethindrone—Asthenia—Paclitaxel—lung cancer	8.47e-05	0.000658	CcSEcCtD
Norethindrone—Nausea—Gemcitabine—lung cancer	8.38e-05	0.000651	CcSEcCtD
Norethindrone—Vomiting—Cisplatin—lung cancer	8.36e-05	0.000649	CcSEcCtD
Norethindrone—Pruritus—Paclitaxel—lung cancer	8.35e-05	0.000649	CcSEcCtD
Norethindrone—Erythema multiforme—Doxorubicin—lung cancer	8.31e-05	0.000646	CcSEcCtD
Norethindrone—Rash—Cisplatin—lung cancer	8.29e-05	0.000644	CcSEcCtD
Norethindrone—Dermatitis—Cisplatin—lung cancer	8.28e-05	0.000643	CcSEcCtD
Norethindrone—Gastrointestinal pain—Docetaxel—lung cancer	8.18e-05	0.000636	CcSEcCtD
Norethindrone—Dizziness—Etoposide—lung cancer	7.96e-05	0.000618	CcSEcCtD
Norethindrone—Immune system disorder—Doxorubicin—lung cancer	7.94e-05	0.000617	CcSEcCtD
Norethindrone—Abdominal pain—Docetaxel—lung cancer	7.91e-05	0.000614	CcSEcCtD
Norethindrone—Dizziness—Paclitaxel—lung cancer	7.81e-05	0.000606	CcSEcCtD
Norethindrone—Nausea—Cisplatin—lung cancer	7.81e-05	0.000606	CcSEcCtD
Norethindrone—Alopecia—Doxorubicin—lung cancer	7.77e-05	0.000603	CcSEcCtD
Norethindrone—Mental disorder—Doxorubicin—lung cancer	7.7e-05	0.000598	CcSEcCtD
Norethindrone—Convulsion—Methotrexate—lung cancer	7.66e-05	0.000595	CcSEcCtD
Norethindrone—Vomiting—Etoposide—lung cancer	7.66e-05	0.000595	CcSEcCtD
Norethindrone—Rash—Etoposide—lung cancer	7.59e-05	0.00059	CcSEcCtD
Norethindrone—Dermatitis—Etoposide—lung cancer	7.58e-05	0.000589	CcSEcCtD
Norethindrone—Headache—Etoposide—lung cancer	7.54e-05	0.000586	CcSEcCtD
Norethindrone—Flatulence—Doxorubicin—lung cancer	7.54e-05	0.000586	CcSEcCtD
Norethindrone—Tension—Doxorubicin—lung cancer	7.51e-05	0.000583	CcSEcCtD
Norethindrone—Vomiting—Paclitaxel—lung cancer	7.51e-05	0.000583	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	7.47e-05	0.00058	CcSEcCtD
Norethindrone—Rash—Paclitaxel—lung cancer	7.44e-05	0.000578	CcSEcCtD
Norethindrone—Dermatitis—Paclitaxel—lung cancer	7.44e-05	0.000578	CcSEcCtD
Norethindrone—Nervousness—Doxorubicin—lung cancer	7.43e-05	0.000577	CcSEcCtD
Norethindrone—Headache—Paclitaxel—lung cancer	7.4e-05	0.000574	CcSEcCtD
Norethindrone—Hypersensitivity—Docetaxel—lung cancer	7.37e-05	0.000573	CcSEcCtD
Norethindrone—Anaphylactic shock—Methotrexate—lung cancer	7.21e-05	0.00056	CcSEcCtD
Norethindrone—Asthenia—Docetaxel—lung cancer	7.18e-05	0.000558	CcSEcCtD
Norethindrone—Nausea—Etoposide—lung cancer	7.15e-05	0.000555	CcSEcCtD
Norethindrone—Pruritus—Docetaxel—lung cancer	7.08e-05	0.00055	CcSEcCtD
Norethindrone—Nausea—Paclitaxel—lung cancer	7.01e-05	0.000545	CcSEcCtD
Norethindrone—Skin disorder—Methotrexate—lung cancer	7e-05	0.000544	CcSEcCtD
Norethindrone—Convulsion—Doxorubicin—lung cancer	6.63e-05	0.000515	CcSEcCtD
Norethindrone—Dizziness—Docetaxel—lung cancer	6.62e-05	0.000514	CcSEcCtD
Norethindrone—Insomnia—Methotrexate—lung cancer	6.52e-05	0.000507	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	6.47e-05	0.000503	CcSEcCtD
Norethindrone—Somnolence—Methotrexate—lung cancer	6.41e-05	0.000498	CcSEcCtD
Norethindrone—Vomiting—Docetaxel—lung cancer	6.36e-05	0.000494	CcSEcCtD
Norethindrone—Dyspepsia—Methotrexate—lung cancer	6.35e-05	0.000493	CcSEcCtD
Norethindrone—Rash—Docetaxel—lung cancer	6.31e-05	0.00049	CcSEcCtD
Norethindrone—Dermatitis—Docetaxel—lung cancer	6.3e-05	0.00049	CcSEcCtD
Norethindrone—Headache—Docetaxel—lung cancer	6.27e-05	0.000487	CcSEcCtD
Norethindrone—Anaphylactic shock—Doxorubicin—lung cancer	6.24e-05	0.000485	CcSEcCtD
Norethindrone—Oedema—Doxorubicin—lung cancer	6.24e-05	0.000485	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Methotrexate—lung cancer	6.23e-05	0.000484	CcSEcCtD
Norethindrone—Fatigue—Methotrexate—lung cancer	6.22e-05	0.000483	CcSEcCtD
Norethindrone—Hydrocortisone—ABCB1—lung cancer	6.12e-05	0.029	CrCbGaD
Norethindrone—Skin disorder—Doxorubicin—lung cancer	6.07e-05	0.000471	CcSEcCtD
Norethindrone—Nausea—Docetaxel—lung cancer	5.94e-05	0.000462	CcSEcCtD
Norethindrone—Gastrointestinal pain—Methotrexate—lung cancer	5.9e-05	0.000458	CcSEcCtD
Norethindrone—Urticaria—Methotrexate—lung cancer	5.73e-05	0.000445	CcSEcCtD
Norethindrone—Abdominal pain—Methotrexate—lung cancer	5.7e-05	0.000443	CcSEcCtD
Norethindrone—Insomnia—Doxorubicin—lung cancer	5.65e-05	0.000439	CcSEcCtD
Norethindrone—Somnolence—Doxorubicin—lung cancer	5.55e-05	0.000431	CcSEcCtD
Norethindrone—Dyspepsia—Doxorubicin—lung cancer	5.5e-05	0.000427	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Doxorubicin—lung cancer	5.39e-05	0.000419	CcSEcCtD
Norethindrone—Fatigue—Doxorubicin—lung cancer	5.38e-05	0.000418	CcSEcCtD
Norethindrone—Hypersensitivity—Methotrexate—lung cancer	5.31e-05	0.000413	CcSEcCtD
Norethindrone—Asthenia—Methotrexate—lung cancer	5.17e-05	0.000402	CcSEcCtD
Norethindrone—Gastrointestinal pain—Doxorubicin—lung cancer	5.11e-05	0.000397	CcSEcCtD
Norethindrone—Pruritus—Methotrexate—lung cancer	5.1e-05	0.000396	CcSEcCtD
Norethindrone—Progesterone—ABCB1—lung cancer	4.99e-05	0.0236	CrCbGaD
Norethindrone—Urticaria—Doxorubicin—lung cancer	4.96e-05	0.000385	CcSEcCtD
Norethindrone—Testosterone—ALB—lung cancer	4.94e-05	0.0234	CrCbGaD
Norethindrone—Abdominal pain—Doxorubicin—lung cancer	4.94e-05	0.000383	CcSEcCtD
Norethindrone—Dizziness—Methotrexate—lung cancer	4.77e-05	0.00037	CcSEcCtD
Norethindrone—Testosterone—ABCB1—lung cancer	4.71e-05	0.0223	CrCbGaD
Norethindrone—Hypersensitivity—Doxorubicin—lung cancer	4.6e-05	0.000357	CcSEcCtD
Norethindrone—Vomiting—Methotrexate—lung cancer	4.59e-05	0.000356	CcSEcCtD
Norethindrone—Rash—Methotrexate—lung cancer	4.55e-05	0.000353	CcSEcCtD
Norethindrone—Dermatitis—Methotrexate—lung cancer	4.54e-05	0.000353	CcSEcCtD
Norethindrone—Headache—Methotrexate—lung cancer	4.52e-05	0.000351	CcSEcCtD
Norethindrone—Asthenia—Doxorubicin—lung cancer	4.48e-05	0.000348	CcSEcCtD
Norethindrone—Pruritus—Doxorubicin—lung cancer	4.42e-05	0.000343	CcSEcCtD
Norethindrone—Nausea—Methotrexate—lung cancer	4.28e-05	0.000333	CcSEcCtD
Norethindrone—Dizziness—Doxorubicin—lung cancer	4.13e-05	0.000321	CcSEcCtD
Norethindrone—Vomiting—Doxorubicin—lung cancer	3.97e-05	0.000308	CcSEcCtD
Norethindrone—Rash—Doxorubicin—lung cancer	3.94e-05	0.000306	CcSEcCtD
Norethindrone—Dermatitis—Doxorubicin—lung cancer	3.93e-05	0.000306	CcSEcCtD
Norethindrone—Headache—Doxorubicin—lung cancer	3.91e-05	0.000304	CcSEcCtD
Norethindrone—Nausea—Doxorubicin—lung cancer	3.71e-05	0.000288	CcSEcCtD
Norethindrone—ALB—Metabolism—PPP2R1B—lung cancer	9.14e-06	0.000154	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GNG11—lung cancer	9.14e-06	0.000154	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GSTM1—lung cancer	9.12e-06	0.000154	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTM2—lung cancer	9.06e-06	0.000153	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CNDP2—lung cancer	9.06e-06	0.000153	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—POMC—lung cancer	9.01e-06	0.000152	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	8.98e-06	0.000151	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTT1—lung cancer	8.92e-06	0.00015	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ALDOA—lung cancer	8.91e-06	0.00015	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GCLC—lung cancer	8.81e-06	0.000149	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP2A6—lung cancer	8.81e-06	0.000149	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—MTMR3—lung cancer	8.81e-06	0.000149	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MAP2K1—lung cancer	8.81e-06	0.000149	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	8.78e-06	0.000148	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CD—lung cancer	8.75e-06	0.000148	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP2E1—lung cancer	8.7e-06	0.000147	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ALDOA—lung cancer	8.7e-06	0.000147	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—MAPK3—lung cancer	8.66e-06	0.000146	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NCOA3—lung cancer	8.65e-06	0.000146	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CYP1A1—lung cancer	8.65e-06	0.000146	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—APOA1—lung cancer	8.64e-06	0.000146	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NQO1—lung cancer	8.6e-06	0.000145	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PGAM1—lung cancer	8.59e-06	0.000145	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—ERCC2—lung cancer	8.58e-06	0.000145	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	8.5e-06	0.000143	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NCOA3—lung cancer	8.44e-06	0.000142	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—MYC—lung cancer	8.42e-06	0.000142	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ADCY1—lung cancer	8.42e-06	0.000142	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ABCG2—lung cancer	8.42e-06	0.000142	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ENO1—lung cancer	8.36e-06	0.000141	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—CREBBP—lung cancer	8.35e-06	0.000141	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	8.33e-06	0.00014	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ENO2—lung cancer	8.25e-06	0.000139	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—HPGDS—lung cancer	8.25e-06	0.000139	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ADCY1—lung cancer	8.21e-06	0.000139	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ABCG2—lung cancer	8.21e-06	0.000139	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PPP2R1B—lung cancer	8.2e-06	0.000138	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP2A7—lung cancer	8.19e-06	0.000138	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—RAF1—lung cancer	8.16e-06	0.000138	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—POMC—lung cancer	8.09e-06	0.000136	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ENO2—lung cancer	8.06e-06	0.000136	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—HPGDS—lung cancer	8.06e-06	0.000136	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SDC4—lung cancer	8.02e-06	0.000135	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PPP2R1B—lung cancer	8e-06	0.000135	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTT1—lung cancer	8e-06	0.000135	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PIK3CB—lung cancer	7.97e-06	0.000134	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GCLC—lung cancer	7.91e-06	0.000133	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP2A6—lung cancer	7.91e-06	0.000133	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	7.88e-06	0.000133	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MDM2—lung cancer	7.84e-06	0.000132	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTT1—lung cancer	7.81e-06	0.000132	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—RAF1—lung cancer	7.81e-06	0.000132	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—STK11—lung cancer	7.76e-06	0.000131	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ERBB2—lung cancer	7.73e-06	0.00013	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GCLC—lung cancer	7.72e-06	0.00013	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP2A6—lung cancer	7.72e-06	0.00013	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—AKT1—lung cancer	7.7e-06	0.00013	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CB—lung cancer	7.62e-06	0.000129	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MTOR—lung cancer	7.62e-06	0.000129	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	7.58e-06	0.000128	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ENO1—lung cancer	7.5e-06	0.000127	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP2E1—lung cancer	7.49e-06	0.000126	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	7.47e-06	0.000126	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—APOA1—lung cancer	7.42e-06	0.000125	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NQO1—lung cancer	7.41e-06	0.000125	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—ALB—lung cancer	7.38e-06	0.000124	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCL8—lung cancer	7.33e-06	0.000124	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ENO1—lung cancer	7.32e-06	0.000123	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IL2—lung cancer	7.32e-06	0.000123	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	7.32e-06	0.000123	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—RRM1—lung cancer	7.3e-06	0.000123	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTA3—lung cancer	7.3e-06	0.000123	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	7.26e-06	0.000122	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	7.19e-06	0.000121	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTP1—lung cancer	7.18e-06	0.000121	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—RAF1—lung cancer	7.07e-06	0.000119	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CASP3—lung cancer	7.01e-06	0.000118	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL2—lung cancer	7e-06	0.000118	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CAT—lung cancer	6.98e-06	0.000118	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—B4GALT5—lung cancer	6.86e-06	0.000116	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	6.85e-06	0.000115	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCND1—lung cancer	6.83e-06	0.000115	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—JUN—lung cancer	6.81e-06	0.000115	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ABCB1—lung cancer	6.79e-06	0.000115	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CG—lung cancer	6.77e-06	0.000114	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP2E1—lung cancer	6.73e-06	0.000113	CbGpPWpGaD
Norethindrone—ALB—Metabolism—STK11—lung cancer	6.68e-06	0.000113	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTA4—lung cancer	6.68e-06	0.000113	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—TYMS—lung cancer	6.67e-06	0.000113	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NQO1—lung cancer	6.65e-06	0.000112	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MMP9—lung cancer	6.63e-06	0.000112	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CDKN1A—lung cancer	6.6e-06	0.000111	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTM1—lung cancer	6.6e-06	0.000111	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PTEN—lung cancer	6.59e-06	0.000111	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—EP300—lung cancer	6.57e-06	0.000111	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP2E1—lung cancer	6.57e-06	0.000111	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	6.51e-06	0.00011	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTA2—lung cancer	6.51e-06	0.00011	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NQO1—lung cancer	6.49e-06	0.00011	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	6.45e-06	0.000109	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—POMC—lung cancer	6.45e-06	0.000109	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SRC—lung cancer	6.39e-06	0.000108	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EP300—lung cancer	6.28e-06	0.000106	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CREBBP—lung cancer	6.28e-06	0.000106	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTA1—lung cancer	6.28e-06	0.000106	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PTEN—lung cancer	6.27e-06	0.000106	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP1A1—lung cancer	6.25e-06	0.000105	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—VEGFA—lung cancer	6.22e-06	0.000105	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ABCC3—lung cancer	6.21e-06	0.000105	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ERCC2—lung cancer	6.2e-06	0.000105	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	6.19e-06	0.000104	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTP1—lung cancer	6.18e-06	0.000104	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—NRAS—lung cancer	6.14e-06	0.000104	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SRC—lung cancer	6.11e-06	0.000103	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CAT—lung cancer	6.01e-06	0.000101	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—AKR1C1—lung cancer	6.01e-06	0.000101	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—STK11—lung cancer	6e-06	0.000101	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—EP300—lung cancer	5.98e-06	0.000101	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CD—lung cancer	5.96e-06	0.0001	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—VEGFA—lung cancer	5.95e-06	0.0001	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—STAT3—lung cancer	5.89e-06	9.94e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—MAPK3—lung cancer	5.89e-06	9.93e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—ALB—lung cancer	5.88e-06	9.92e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—NRAS—lung cancer	5.88e-06	9.91e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—STK11—lung cancer	5.85e-06	9.87e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ABCB1—lung cancer	5.85e-06	9.87e-05	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—AKT1—lung cancer	5.84e-06	9.85e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—UGT1A1—lung cancer	5.84e-06	9.85e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—TYMS—lung cancer	5.75e-06	9.69e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTM1—lung cancer	5.68e-06	9.58e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MAPK3—lung cancer	5.63e-06	9.5e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	5.63e-06	9.49e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GNG11—lung cancer	5.63e-06	9.49e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTP1—lung cancer	5.55e-06	9.36e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MYC—lung cancer	5.48e-06	9.24e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTP1—lung cancer	5.42e-06	9.13e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CAT—lung cancer	5.4e-06	9.11e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP1A1—lung cancer	5.38e-06	9.08e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	5.37e-06	9.05e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—APOA1—lung cancer	5.36e-06	9.05e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ALDOA—lung cancer	5.36e-06	9.04e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EGFR—lung cancer	5.36e-06	9.03e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ERCC2—lung cancer	5.34e-06	9.01e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—KRAS—lung cancer	5.29e-06	8.92e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CAT—lung cancer	5.27e-06	8.89e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ABCB1—lung cancer	5.25e-06	8.86e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NCOA3—lung cancer	5.2e-06	8.78e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CB—lung cancer	5.19e-06	8.76e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—TYMS—lung cancer	5.16e-06	8.7e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PTGS2—lung cancer	5.14e-06	8.68e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTM1—lung cancer	5.1e-06	8.6e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ABCG2—lung cancer	5.06e-06	8.54e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ADCY1—lung cancer	5.06e-06	8.54e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—KRAS—lung cancer	5.06e-06	8.53e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—TYMS—lung cancer	5.03e-06	8.49e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTM1—lung cancer	4.98e-06	8.39e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ENO2—lung cancer	4.96e-06	8.37e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—HPGDS—lung cancer	4.96e-06	8.37e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PPP2R1B—lung cancer	4.93e-06	8.32e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CG—lung cancer	4.9e-06	8.26e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PIK3CA—lung cancer	4.86e-06	8.2e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP1A1—lung cancer	4.83e-06	8.15e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTT1—lung cancer	4.81e-06	8.12e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ERCC2—lung cancer	4.79e-06	8.09e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GCLC—lung cancer	4.76e-06	8.03e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP2A6—lung cancer	4.76e-06	8.03e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP1A1—lung cancer	4.72e-06	7.96e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TP53—lung cancer	4.7e-06	7.93e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ERCC2—lung cancer	4.68e-06	7.89e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—POMC—lung cancer	4.66e-06	7.86e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PIK3CA—lung cancer	4.65e-06	7.84e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—APOA1—lung cancer	4.62e-06	7.79e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CREBBP—lung cancer	4.54e-06	7.66e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ENO1—lung cancer	4.51e-06	7.61e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TP53—lung cancer	4.5e-06	7.58e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—HRAS—lung cancer	4.5e-06	7.58e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PTEN—lung cancer	4.49e-06	7.57e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.42e-06	7.46e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CD—lung cancer	4.31e-06	7.26e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HRAS—lung cancer	4.3e-06	7.25e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—EP300—lung cancer	4.28e-06	7.22e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ALB—lung cancer	4.25e-06	7.17e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CG—lung cancer	4.22e-06	7.11e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—APOA1—lung cancer	4.15e-06	7e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL6—lung cancer	4.12e-06	6.94e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—APOA1—lung cancer	4.05e-06	6.83e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP2E1—lung cancer	4.05e-06	6.82e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—POMC—lung cancer	4.01e-06	6.77e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NQO1—lung cancer	4e-06	6.75e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	3.97e-06	6.7e-05	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—AKT1—lung cancer	3.97e-06	6.7e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CREBBP—lung cancer	3.91e-06	6.6e-05	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—AKT1—lung cancer	3.8e-06	6.4e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CG—lung cancer	3.79e-06	6.39e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CB—lung cancer	3.75e-06	6.33e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PTGS2—lung cancer	3.72e-06	6.27e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CD—lung cancer	3.71e-06	6.25e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CG—lung cancer	3.7e-06	6.23e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—STK11—lung cancer	3.61e-06	6.08e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—POMC—lung cancer	3.6e-06	6.08e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—POMC—lung cancer	3.52e-06	5.93e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CREBBP—lung cancer	3.51e-06	5.92e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CREBBP—lung cancer	3.43e-06	5.78e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTP1—lung cancer	3.34e-06	5.63e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CD—lung cancer	3.33e-06	5.61e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ALB—lung cancer	3.29e-06	5.54e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CD—lung cancer	3.25e-06	5.48e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CAT—lung cancer	3.25e-06	5.48e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PTEN—lung cancer	3.24e-06	5.47e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CB—lung cancer	3.23e-06	5.45e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ALB—lung cancer	3.21e-06	5.41e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PTGS2—lung cancer	3.2e-06	5.4e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PIK3CA—lung cancer	3.16e-06	5.34e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ABCB1—lung cancer	3.16e-06	5.33e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—TYMS—lung cancer	3.1e-06	5.23e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—EP300—lung cancer	3.09e-06	5.22e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTM1—lung cancer	3.07e-06	5.17e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP1A1—lung cancer	2.91e-06	4.9e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CB—lung cancer	2.9e-06	4.89e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ERCC2—lung cancer	2.88e-06	4.86e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PTGS2—lung cancer	2.87e-06	4.85e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CB—lung cancer	2.83e-06	4.78e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PTGS2—lung cancer	2.81e-06	4.73e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PTEN—lung cancer	2.79e-06	4.71e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—EP300—lung cancer	2.66e-06	4.49e-05	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—AKT1—lung cancer	2.59e-06	4.36e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PTEN—lung cancer	2.51e-06	4.23e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—APOA1—lung cancer	2.49e-06	4.21e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PTEN—lung cancer	2.45e-06	4.13e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—EP300—lung cancer	2.39e-06	4.03e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—EP300—lung cancer	2.33e-06	3.94e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PIK3CA—lung cancer	2.29e-06	3.86e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CG—lung cancer	2.28e-06	3.84e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—POMC—lung cancer	2.17e-06	3.66e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CREBBP—lung cancer	2.11e-06	3.56e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CD—lung cancer	2e-06	3.38e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ALB—lung cancer	1.98e-06	3.33e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PIK3CA—lung cancer	1.97e-06	3.32e-05	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—AKT1—lung cancer	1.87e-06	3.15e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PIK3CA—lung cancer	1.77e-06	2.98e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CB—lung cancer	1.74e-06	2.94e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PTGS2—lung cancer	1.73e-06	2.92e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PIK3CA—lung cancer	1.73e-06	2.91e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—AKT1—lung cancer	1.61e-06	2.71e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PTEN—lung cancer	1.51e-06	2.54e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—AKT1—lung cancer	1.44e-06	2.44e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—EP300—lung cancer	1.44e-06	2.42e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—AKT1—lung cancer	1.41e-06	2.38e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PIK3CA—lung cancer	1.06e-06	1.79e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—AKT1—lung cancer	8.69e-07	1.47e-05	CbGpPWpGaD
